Citations

Clear

3030 citation(s) found for "Susan, M".

Enhancing Diversity, Equity and Inclusion in Clinical Research: Strategies Used By Clinical Investigators
Wilson, Hope P. , Kuaban, Alain, Kitchen, Cristina, Geyer, Susan, Goldenberg, Neil A. , Kitchen, Cristina, Tomlinson, George

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7740-7740

10.1182/blood-2024-211407 Get It

Introduction Clinical trials are the avenue whereby the effects of interventions on health-related outcomes are evaluated. It is imperative that these trials are diverse and inclusive to reduce disparities in overall health outcomes as individuals can experience the same disease differently. When populations are not underrepresented in clinical trials, the results are not generalizable. Despite efforts to facilitate diverse representation across clinical trials, including guidance from the United States Food and Drug Administration, gaps persist in regard to understanding approaches to achieve this goal. With this in mind, we designed an international survey-based research study with the primary objectives to understand current tools and tactics investigators are employing in their clinical research and to identify gaps to ensure diversity, equity and inclusion (DEI). Methods This study was approved through the Institutional Review Board at the University of Alabama at Birmingham. The survey was developed using QuestionPro software (Austin, TX, USA). The target population for this study was the members of the American Society of Hematology (ASH) along with individuals who attended or were presenting authors at the 2023 ASH Annual Meeting, and individuals on the “This Week in Blood email list.” Surveys were distributed via email to potential participants between April and July 2024. Reminder emails were sent on 2 occasions. The survey was also advertised via various social media platforms (e.g., Twitter, Instagram, Facebook and LinkedIn). No incentives were provided for completion of the survey. In the introductory email, participants were assured of the anonymous nature of the survey and were instructed to proceed only if they consented to participate voluntarily in this research study. Results The survey was viewed by 5171 individuals. There were 774 total responses, for a response rate of 15%. Complete responses were provided by 502 respondents. Fifty-seven percent of survey respondents were based in the United States and 56% were ASH members. Seventy-one percent of respondents were clinicians, of which the majority (74%) were primarily adult providers and 86% reported hematology as their clinical specialty, a large proportion of whom were malignant hematologists. Regarding clinical research involvement over the last 5 years, 29% identified as sub investigators, 23% were site principal investigators (PI) in multicenter studies, and 19% reported roles as overall PI for studies. Respondents reported employing tactics to enhance DEI in all phases of prospective clinical research studies. Nineteen percent stated that they engage patients in the research planning phase, in protocol design, review and revision. During the implementation phase, 21% reported outreach to community providers to increase trial awareness and encourage patient referrals. Patient groups were engaged to disseminate study findings in language that patients can understand by 22% of respondents. Among the tools that were used, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidance on Clinical Practice was the most frequently reported tool in the planning phase (24%). Respondents reported no consistent use of any tool or tactic during the implementation and dissemination phases of clinical research and a large proportion reported using no tools to enhance DEI in their studies. Seventy-four percent of respondents reported that they had received no formal training or guidance on how to incorporate DEI principles and enhance DEI in clinical research. There were mixed opinions on the importance of incorporating DEI principles into clinical research, ranging from acknowledging the significance to dismissal of the concept. The majority of survey respondents (79%) indicated willingness to participate in a learning community developed by ASH. Conclusions The findings from this survey not only shed light on what resources and strategies investigators are employing most and at what stages of their clinical research, but also highlight a critical need for more training on and awareness of resources for incorporating DEI principles into clinical research. Results of this study will empower ASH to develop comprehensive resources that resonate with the dynamic needs of trialists in the pursuit of a more equitable and effective approach to clinical research.
Association between Sleep Traits and Risk of Non-Hodgkin's Lymphoma Subtypes: A Mendelian Randomization Study in the International Lymphoma (InterLymph) Epidemiology Consortium
Shah, Pankhil, Crawford, Brittany, Macauda, Angelica , Hildebrandt, Michelle A.T., Caporaso, Neil E. , Yeager, Meredith, Dean, Michael , Goldin, Lynn R. , Camp, Nicola J. , Casabonne, Delphine , Nieters, Alexandra, Chanock, Stephen J, Machiela, Mitchell J. , Conry, Michael , Park, Han La, Cheah, Simon , Brown, Elizabeth E. , Vachon, Celine M. , Berndt, Sonja, McKay, James , Hjalgrim, Henrik, Sucheston‐Campbell, Lara, Machiela, Mitchell J , Merchant, Anwar T. , Birmann, Brenda M. , Hildebrandt, Michelle A.T. , Norman, Aaron D. , Yeager, Meredith , Vivo, Immaculata De , Waller, Rosalie G. , Canzian, Federico , Unal, Pelin, Ziv, Elad , Marinac, Catherine R. , Nieters, Alexandra , Hofmann, Jonathan N. , Vachon, Celine M. , Slager, Susan L. , Wang, Sophia , Vijai, Joseph , Smith-Byrne, Karl , Clay‐Gilmour, Alyssa

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 6182-6182

10.1182/blood-2024-199373 Get It

Introduction: Over 80,000 new cases of Non-Hodgkin's Lymphoma (NHL) are diagnosed annually, but modifiable risk factors are largely unknown. Circadian disruption has been identified as a risk factor for several cancers, including breast and prostate cancer, and affects immune cells such as Natural Killer (NK) cells and T-helper cells. Disruptions in circadian rhythms can lead to aberrant immune cell trafficking and proliferation. Despite this biological connection, evidence linking circadian disruptions to NHL remains inconclusive. Only single Mendelian Randomization (MR) study (PMID: 32895918) has explored the causal relationship between sleep traits and overall NHL risk, without examining NHL subtypes. Studies have shown distinct risk factor profiles among NHL subtypes. Therefore, this study aims to investigate the causal relationship between sleep traits and NHL subtypes in European populations using MR. Methods: We conducted a two-sample MR analyses using genome-wide association studies (GWAS) summary data on sleep traits and NHL subtypes. The GWAS summary statistics on sleep traits were obtained from publicly available UKBiobank datasets. The sleep traits analyzed included chronotype (N=449,734), insomnia (N=237,627), sleep duration (N=446,118), daytime sleepiness (N=452,071), short sleep (N=411,934), and long sleep (N=339,926). Only independent, genome-wide significant SNPs (p < 5×10-8) were considered as valid instruments. The NHL subtype-specific summary statistics came from the InterLymph including follicular lymphoma (FL: N=6,508 cases / 64,183 controls), mantle cell lymphoma (MCL: N=1,169 cases / 61,603 controls), and Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL: N=1,697 cases / 59,333 controls). Our primary analysis used the random-effects inverse-variance weighted (IVW) method. In addition, we employed MR-Egger to adjust for directional pleiotropy. Heterogeneity in the MR results was evaluated with Cochran's Q statistic. Results: The IVW method did not identify any statistically significant causal association between sleep traits and the risk of NHL subtypes (FL,MCL,WM/LPL), but did yield several intriguing associations. Chronotype (early rising) showed a tendency towards a marginally an increased NHL risk across subtypes [Odds ratio (OR) range: 1.07 - 2.56]. Conversely, a decreased risk was noted for long sleep (≥ 9 hours vs. 7-8 hours) [OR range: 0.19 - 0.62], insomnia [OR range: 0.72 - 0.88], and short sleep (excludes MCL) [OR range: 0.12 - 0.72]. Confidence limit for long sleep was wide due to small number of variants (N=8). The MR-Egger regression analysis did not provide evidence of significant directional horizontal pleiotropy. The F-statistics for all sleep traits were greater than 10 indicating absences of weak instrument bias. Conclusions: Our study found no statistically significant associations between sleep traits and three NHL subtypes (FL, MCL, WM/LPL) in European populations. However, we observed potential influences of chronotype, long and short sleep, and insomnia on NHL risk. These findings align with and extend previous MR study by providing subtype-specific insights. Future directions include expanding our analysis to additional NHL subtypes, generating polygenic risk scores, and conducting stratified analyses using the InterLymph population. These efforts aim to further elucidate the complex relationship between sleep characteristics and NHL risk across diverse subtypes and populations.
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2- mutant clonal hematopoiesis in inflammatory response
Ismail, Wazim Mohammed , Binder, Moritz , Kim, Minsuk , Geyer, Susan M. , Mazzone, Amelia , Finke, Christy M. , Mangaonkar, Abhishek A. , Lee, Jeong‐Heon , Kim, Kwan‐Hyun , Simon, Vernadette, Rohakthar, Fariborz Rakhshan, Munankarmy, Amik , Byeon, Seul Kee , Schwager, Susan M., Harington, Jonathan J., Snyder, Melissa R. , Wieben, Eric D. , Gaspar‐Maia, Alexandre , Patnaik, Mrinal M. , Mohammed Ismail, Wazim , Fernandez, Jenna A., Binder, Moritz , Kim, Minsuk , Mazzone, Amelia , Lee, Jeong-Heon , Wang, Liguo , Kim, Kwan Hyun , Simon, Vernadette A, Rakhshan Rohakthar, Fariborz, Munankarmy, Amik , Byeon, Seul Kee , Harrington, Jonathan J. , Robertson, Keith D , Pandey, Akhilesh , Gaspar-Maia, Alexandre , Patnaik, Mrinal , Fernandez, Jenna , Lasho, Terra L. , Wang, Liguo , Robertson, Keith D. , Pandey, Akhilesh , Chia, Nicholas

Mayo Clinic

Blood Advances | December 4, 2024 | Volume: 9 | Issue: 2 | Pages: 402-416

10.1182/bloodadvances.2024014467 | PMID 39631069 Get It

Abstract DNMT3A and TET2 are epigenetic regulator genes commonly mutated in age-related clonal hematopoiesis (CH). Despite having opposed epigenetic functions, these mutations are associated with increased all-cause mortality and a low risk for progression to hematologic neoplasms. Although individual impacts on the epigenome have been described using different model systems, the phenotypic complexity in humans remains to be elucidated. Here, we make use of a natural inflammatory response occurring during coronavirus disease 2019 (COVID-19), to understand the association of these mutations with inflammatory morbidity (acute respiratory distress syndrome [ARDS]) and mortality. We demonstrate the age-independent, negative impact of DNMT3A mutant (DNMT3Amt) CH on COVID-19–related ARDS and mortality. Using single-cell proteogenomics we show that DNMT3A mutations involve myeloid and lymphoid lineage cells. Using single-cell multiomics sequencing, we identify cell-specific gene expression changes associated with DNMT3A mutations, along with significant epigenomic deregulation affecting enhancer accessibility, resulting in overexpression of interleukin-32 (IL-32), a proinflammatory cytokine that can result in inflammasome activation in monocytes and macrophages. Finally, we show with single-cell resolution that the loss of function of DNMT3A is directly associated with increased chromatin accessibility in mutant cells. Hence, we demonstrate the negative prognostic impact of DNMT3Amt CH on COVID-19–related ARDS and mortality. DNMT3Amt CH in the context of COVID-19, was associated with inflammatory transcriptional priming, resulting in overexpression of IL32. This overexpression was secondary to increased chromatic accessibility, specific to DNMT3Amt CH cells. DNMT3Amt CH can thus serve as a potential biomarker for adverse outcomes in COVID-19.
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Cloyd, Jordan M. , Sarna, Angela, Arango, Matthew J. , Bates, Susan E. , Bloomston, Mark, Ferrone, Cristina R., Gambino, Patricia, Goenka, Ajit H. , Hall, William A. , Jayaraman, Shiva , Kambadakone, Avinash, Ko, Andrew , Kooby, David A. , Krishna, Somashekar G. , Larsson, Liliana, Massarweh, Nader N. , Mikhail, Sameh , Palta, Manisha , Petzel, Maria Q. B., Philip, P. A., Mina, Daniel Santa , Sohal, Davendra , Sundaresan, Tilak , Tsai, Susan, Vreeland, Timothy J. , Walston, Steve, Wo, Jennifer Y. , Snyder, Rebecca A. , He, Jin , Tsai, Susan , Krishna, Somashekar G , Santa Mina, Daniel , Bates, Susan E , Bhutani, Manoop S. , Chung, Vincent , Dotan, Efrat , Goodman, Karyn A. , He, Jing , Hogg, Melissa E. , Katz, Matthew H. G. , Khorana, Alok A. , Koay, Eugene J. , Lee, Richard T. , Maitra, Anirban , Muzaffar, Mahvish , O’Reilly, Eileen M. , Reyngold, Marsha , Turner, Kea L. , Washington, Mary Kay , Williams, Terence M. , Snyder, Rebecca A.

Mayo Clinic

JAMA Surgery | December 4, 2024 | Volume: 160 | Issue: 2 | Pages: 172

10.1001/jamasurg.2024.5191 | PMID 39630427 Get It

Importance Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and the standards for optimal delivery of NT have not been defined. Objective To develop consensus best practices for delivering NT to patients with localized PDAC. Design, Setting, and Participants This study used a modified Delphi approach consisting of 2 rounds of voting, and a series of virtual conferences (from October to December 2023) to reach expert consensus on candidate best practice statements generated from a systematic review of the literature and expert opinion. An interdisciplinary panel was formed including 47 North American experts from surgical, medical, and radiation oncology, radiology, pathology, gastroenterology, integrative oncology, anesthesia, pharmacy, nursing, cancer care delivery research, and nutrition as well as patient and caregiver stakeholders. Main Outcome and Measures Statements that reached 75% agreement or greater were included in final consensus statements. Results Of the 47 participating panel members, 27 (57.64%) were male, and the mean (SD) age was 47.6 (8.2) years. Physicians reported completing training a mean (SD) 14.6 (8.6) years prior and seeing a mean (SD) 110.6 (38.4) patients with PDAC annually; 35 (77.7%) were in academic practice. Final consensus was reached on 82 best practices for delivering NT. Of these, 38 statements focused on pre-NT practices, including diagnosis and staging (n = 15), evaluation and optimization (n = 20), and decision-making (n = 3); 29 statements defined best practices during NT, including initiation (n = 3), delivery of therapy (n = 8), restaging practices (n = 12), and management of complications during NT (n = 6); and 15 best practices were identified to guide treatment post-NT, focusing on surgery (n = 7), pathology (n = 4), and follow-up (n = 3). Conclusions Using a modified Delphi consensus technique, best practice guidelines were developed focusing on the optimal standards for delivering NT to patients with localized PDAC. Given the prognostic importance of completing multimodality therapy, efforts to standardize and optimize the delivery of NT represent an immediate opportunity to decrease care variation and improve outcomes for patients with PDAC. Future research should focus on validating and implementing best practice standards into clinical practice.
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
Fatola, Ayotola , Evans, Michael D. , Brown, Jenna , Davis, Elizabeth E. , Johnson, Andrew D. , Antun, Ana G., Farland, Andrew M., Metjian, Ara , Park, Yara A. , Ridder, Gustaaf de, Gibson, Briana, Eubanks, Susan, Akwaa, Frank, Clover, Todd, Sadler, J. Evan, Upreti, Harsh Vardhan , Kocher, Nicole K. , Gangaraju, Radhika , Masias, Camila , Mazepa, Marshall , Metjian, Ara , Kasthuri, Raj S , Baumann Kreuziger, Lisa , Sridharan, Meera , McCrae, Keith R , Lim, Ming Y , Zheng, X Long , Raval, Jay S , Cataland, Spero R , Mazepa, Marshall A , Evans, Michael D , Davis, Elizabeth, Woods, Ryan, Kasthuri, Raj S. , Liles, Darla , Kreuziger, Lisa Baumann , Sridharan, Meera , Go, Ronald S. , McCrae, Keith R. , Zheng, X. Long , Raval, Jay S. , Cataland, Spero R. , Chaturvedi, Shruti

Mayo Clinic

Blood Advances | December 3, 2024 | Volume: 9 | Issue: 2 | Pages: 417-424

10.1182/bloodadvances.2024013313 | PMID 39626301 Get It

Abstract Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody-mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab effect is maintained with subsequent treatment courses has not been studied. Using the United States Thrombotic Microangiopathy Consortium (USTMA) retrospective iTTP registry, we evaluated clinical relapse-free survival (RFS) with subsequent courses of rituximab treatment in multiply relapsing patients. Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the second or subsequent rituximab-treated episode than the first (2.1 vs 6.0 years; P = .04). White patients’ clinical relapse risk after the second and subsequent rituximab courses was not significantly different compared with the first (hazard ratio [HR], 1.86; 95% confidence interval [CI], 0.22-15.80; P = .57), whereas for Black patients, clinical relapse risk was significantly higher after the second or subsequent courses (HR, 2.82; 95% CI, 1.52-5.24; P = .001). In the prospective cohort, overall RFS progressively shortened after each episode of rituximab treatment with the first episode having the longest RFS (2.8 years; interquartile range, 2.0-6.0) and this loss of response durability was most pronounced in Black patients. The durability of rituximab’s effect declines with subsequent treatments, which is more pronounced in Black patients, who may benefit from closer monitoring and alternative immunomodulatory approaches such as maintenance rituximab and consideration of other agents.
A Video-Based Learning Module Is an Effective Way to Teach the Interpretation of Preoperative Electrodiagnostic Studies
Taylor, R. W., Patterson, J. Megan M. , Llaneras, Noah S. , Pripotnev, Stahs , Wu, Kitty Y. , Mackinnon, Susan E., Mackinnon, Susan E. , Zhang, Justin K.

Mayo Clinic

Plastic & Reconstructive Surgery | November 26, 2024 | Volume: 155 | Issue: 6 | Pages: 1024-1032

10.1097/prs.0000000000011907 | PMID 39592185 Get It

Background: Electrodiagnostic studies are critical for surgical decision-making in nerve injuries. Surgeons typically rely on the electrodiagnostician’s reports and lack formal training in electrodiagnostic study interpretation. This knowledge gap highlights a need for accessible and effective educational resources for surgeons to improve their understanding of electrodiagnostic studies and enhance patient care. Methods: The educational module consisted of a prelecture knowledge assessment, a 42-minute video lecture on interpreting electrodiagnostic study results, and a postlecture knowledge assessment. Knowledge retention was assessed by means of an additional survey distributed 3 months after module completion. Results: This study, involving 119 participants (79% attending surgeons, 8% fellows, 9% surgical residents, and 2% who described their position as “other”), demonstrated that a 42-minute video-based learning module significantly improved knowledge of electrodiagnostic study interpretation. Median scores increased from 7 to 9 (P < 0.001), with improvement persisting at 3 months (median retention score, 11; P < 0.025). Among surgeons completing the 3-month assessment, 65.5% reported that knowledge gained from the module had changed their clinical practice. Conclusion: This study demonstrates that a concise, video-based learning module can effectively enhance surgeon knowledge of electrodiagnostic study interpretation and may serve as a valuable tool for surgical education and improving patient selection in nerve surgery.
Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification
Landau, Susan, Baker, Suzanne L. , Boswell, Martin S., Lee, JiaQie, Taggett, Jacinda , Ward, Tyler J. , Chadwick, Trevor, Murphy, Alice, DeCarli, Charles, Jack, Clifford R. , Jagust, William J. , Initiative, for the U.S. POINTER Study Group and for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , DeCarli, Charles , Jack, Clifford R , Harrison, Theresa M. , Schwarz, Christopher G. , Vemuri, Prashanthi , Koeppe, Robert A. , Initiative, for the U.S. POINTER Study Group and for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | November 19, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14378 | PMID 39559932 Get It

Abstract INTRODUCTION A key goal of the Alzheimer's Disease NeuroImaging Initiative (ADNI) positron emission tomography (PET) Core is to harmonize quantification of β‐amyloid (Aβ) and tau PET image data across multiple scanners and tracers. METHODS We developed an analysis pipeline (Berkeley PET Imaging Pipeline, B‐PIP) for ADNI Aβ and tau PET images and applied it to PET data from other multisite studies. Steps include image pre‐processing, refacing, magnetic resonance imaging (MRI)/PET co‐registration, visual quality control (QC), quantification of tracer uptake, and standardization of Aβ and tau standardized uptake value ratios (SUVrs) across tracers. RESULTS Measurements from 10,105 cross‐sectional and longitudinal Aβ and tau PET scans acquired in several studies between 2010 and 2024 can be processed, harmonized, and directly merged across tracers and cohorts. DISCUSSION The B‐PIP developed in ADNI is a scalable image harmonization approach used in several observational studies and clinical trials that facilitates rigorous Aβ and tau PET quantification and data sharing. Highlights Quantitative results from ADNI Aβ and tau PET data are generated using a rigorous, scalable image processing pipeline This pipeline has been applied to PET data from several other large, multisite studies and trials Quantitative outcomes are harmonizable across studies and are shared with the scientific community
AAPM task group report 314: Fault recovery in external beam radiation therapy
Sutlief, Steven , Buckey, C, Hadley, Scott, Curran, Bruce, Siochi, R , Tripathi, Sugata , Perrin, D, Young, Cheryl, Negrut, Cristina, Koehl, Susan, Shi, Jie, Ibbott, Geoffrey S. , Young, Cheryl, Robertson, Ian

Mayo Clinic

Medical Physics | November 15, 2024 | Volume: 52 | Issue: 1 | Pages: 21-44

10.1002/mp.17502 | PMID 39545768 Get It

Abstract Task Group (TG) 314 of the American Association of Physicists in Medicine (AAPM) was charged to develop guidance for recovering from fault states in radiation therapy, specifically regarding the delivery of photon or electron beams using a linear accelerator (linac) including ancillary systems. The fault conditions addressed may involve software, hardware, or a combination of causes. The report provides detailed recommendations for the proactive steps to be taken before a fault, the actions to be taken at the time of a fault, and the safety steps before returning a linac to clinical service, as well as the activities that device manufacturers and standard organizations can do to prevent and resolve the faults. A user‐maintained log of prior faults; establishment of remote access by the vendor; and user training in emergency gantry, couch, and door motions are all useful proactive steps. At the moment of downtime and after ensuring the safety of the patient, the report stresses the importance of capturing fault information, prompt contact with the service engineer after the initial assessment, and considerations for communicating the estimated duration before the linac is returned to service. The medical physicist has a critical responsibility to assess the impact of the fault on patient care. Before resuming clinical use, the medical physicist must both determine the level of testing required to ensure safe operation of the linac and ensure any partially or totally delivered treatments have been correctly saved for accurate completion of the treatment fraction. The report stresses the roles of the radiation therapist, medical physicist, and service engineer to efficiently and safely address linac downtime. The appendices contain a description of the efforts of several organizations regarding linac safety: Integrating the Healthcare Enterprise—Radiation Oncology, International Standards Organization/International Electrotechnical Commission, Radiation Oncology Safety Stakeholder Initiative, and the AAPM Vendor Relations and Product Usability Subcommittee. Disclaimer: The recommendations of this TG should not be used to establish regulations. These recommendations are guidelines for Qualified Medical Physicists and others to use and appropriately interpret for their institution and clinical setting. Each institution may have site‐specific or state‐mandated needs and requirements which may modify their usage of these recommendations.
Abstract 4137155: Relationship between Subclinical Myocardial Injury and Global Cognitive Performance: The Multi-Ethnic Study of Atherosclerosis (MESA)
Tomar, Shubham , Moraes, Aline , Huang, Shi, Nasir, Khurram, Heckbert, Susan R. , Hughes, Timothy M. , Sandoval, Yader , Jaffe, Allan S. , Lidani, Kárita Cláudia Freitas , Nasir, Khurram , Blaha, Michael Joseph , deFilippi, Christopher R. , Jaffe, Allan S. , DeFilippis, Andrew P.

Mayo Clinic

Circulation | November 13, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4137155 Get It

Background: With demographic trends transitioning towards older adults, dementia and cognitive impairment are predicted to increase dramatically. We aim to elucidate the relationship between subclinical myocardial injury, as indicated by asymptomatic increased levels of high-sensitivity cardiac Troponin (hs-cTnT), and cognitive performance. Methods: We studied MESA participants from Exam 1 (2000-02) to Exam 6 (2016-18), categorizing them based on baseline hs-cTnT at Exam 1. Cognitive decline was defined as a decrease of ≥5 units in CASI between Exam 5&6. We used Pearson correlation and linear regression to analyze the association of hs-cTnT levels with CASI scores, and logistic regression to examine the association with cognitive decline. We also explored the relationship between different hs-cTnT categories and cognitive measures. Models were adjusted for demographics, lifestyle, APOE status, comorbidities, and medication use ( Figure ). Results: 4445 participants had both baseline hs-cTnT and valid Exam 5 CASI scores while only 1776 participants had valid Exam 6 CASI scores. Cohort was predominantly female (53%), mean age of 60 years, and 27% had at least one APOE e4 allele. Median hs-cTnT was 6.32 ng/L, and median CASI scores were 89 at Exam 5 and 91.5 at Exam 6. We found a negative correlation between the log-hs-cTnT at Exam 1 and Exam 5 with CASI scores at Exam 5. An increase of one unit in log-hs-cTnT level was associated with a decrease of 0.67 (CI -1.17, -0.17) in CASI and corresponded to higher odds (OR: 1.44; CI 1.05-1.95) of cognitive decline, after adjusting for covariates. When comparing various categories of hs-cTnT with category 1, we observe that the odd of cognitive decline increases as the category increases. However, this trend does not hold for category 5 with significantly lower sample size ( Figure ). Conclusion: Our findings indicate an inverse relationship between hs-cTnT and cognitive function years later, which is significantly attenuated by known risk factors for cognitive decline. Further research is needed to determine hs-cTnT as a predictor of future global cognitive functions.
Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Baden, Lindsey R. , Almyroudis, Nikolaos G. , Angarone, Michael , Baluch, Aliyah , Barros, Nicolas , Buss, Brian, Cohen, Stuart H. , Cooper, Brenda , Chiang, Augusto Dulanto , Boghdadly, Zeinab El , Gregg, Kevin , Hakim, Hana , Ho, Dora Y. , Lee, Rachael , Lee, Francesca , Logan, Cathy , Manley, Kristen, Pisano, Jennifer , Saullo, Jennifer L. , Schuster, Mindy G. , Seo, Susan K. , Taplitz, Randy , Topal, Jeffrey , Wilson, John , Zimmer, Andrea , Cassara, Carly J., Diwan, Zeenat, Swaminathan, Sankar , Khawaja, Fareed , Multani, Ashrit , Pande, Anupam , Pergam, Steven A. , Shoham, Shmuel , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 617-644

10.6004/jnccn.2024.0056 | PMID 39536464 Get It

There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. Several risk factors can predispose these patients to infectious complications. Some such factors include immunocompromised states like neutropenia, allogeneic hematopoietic cell transplantation, and graft-versus-host disease, while others include immunosuppressive agents like corticosteroids, purine analogs, monoclonal antibodies, and other emerging cancer therapeutics like CAR T-cell therapy. The NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections address infection concerns that may be observed in these immunocompromised populations and characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This paper highlights 2 recently updated sections of the guidelines, namely, infection concerns related to CAR T-cell therapy and antimicrobial prophylaxis recommendations, including vaccination, in patients at high-risk for infections.